Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Feb 13, 2023 6:52pm
230 Views
Post# 35284115

RE:Asco Gu abstract released

RE:Asco Gu abstract releasedAs expected, based on the deadline for abstract submission back in Oct. The abstract reports.
Assessment 90 Day 180 Day 270 Day 360 Day 450 Day
CR 50% 47% 41% 35% 21%
IR 16% 26% 22% 12% 13%
Total Response 66% 74% 63% 46% 33%
Evaluable Patients 38 34 32 26 24

Whereas the Nov 29 data release, was:
Assessment 90 Day 180 Day 270 Day 360 Day 450 Day
Complete Response (“CR”) 53% 45% 41% 29% 28%
Indeterminate Response (“IR”) 14% 24% 19% 15% 10%
Total Response (“CR + IR”) 67% 69% 60% 44% 38%
Evaluable Patients 43 38 37 34 29

So the abscract summary is not as curret as the TLT data releases are.

The poster itself is where the interesting specific will be reported so that is what I'm looking forward to. For example, it may be the first ever clear display of the patients compared to TLT's releases.

I had a glance at the rest of the abstracts with key word NMIBC and there doesn't seem to be anythig earthshattering by way of competitors with other data.
<< Previous
Bullboard Posts
Next >>